MXPA02008097A - Formulacion de propol con inhibicion microbiana mejorada. - Google Patents

Formulacion de propol con inhibicion microbiana mejorada.

Info

Publication number
MXPA02008097A
MXPA02008097A MXPA02008097A MXPA02008097A MXPA02008097A MX PA02008097 A MXPA02008097 A MX PA02008097A MX PA02008097 A MXPA02008097 A MX PA02008097A MX PA02008097 A MXPA02008097 A MX PA02008097A MX PA02008097 A MXPA02008097 A MX PA02008097A
Authority
MX
Mexico
Prior art keywords
formulation
propofol
microbial inhibition
enhanced microbial
propofol formulation
Prior art date
Application number
MXPA02008097A
Other languages
English (en)
Spanish (es)
Inventor
Jie Fei Din
Original Assignee
Amphastar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amphastar Pharmaceuticals Inc filed Critical Amphastar Pharmaceuticals Inc
Publication of MXPA02008097A publication Critical patent/MXPA02008097A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA02008097A 2000-12-20 2001-07-16 Formulacion de propol con inhibicion microbiana mejorada. MXPA02008097A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/745,018 US6399087B1 (en) 2000-12-20 2000-12-20 Propofol formulation with enhanced microbial inhibition
PCT/US2001/022248 WO2002049631A1 (en) 2000-12-20 2001-07-16 Propofol formulation with enhanced microbial inhibition

Publications (1)

Publication Number Publication Date
MXPA02008097A true MXPA02008097A (es) 2004-09-10

Family

ID=24994883

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02008097A MXPA02008097A (es) 2000-12-20 2001-07-16 Formulacion de propol con inhibicion microbiana mejorada.

Country Status (11)

Country Link
US (1) US6399087B1 (cg-RX-API-DMAC7.html)
EP (1) EP1250130A4 (cg-RX-API-DMAC7.html)
JP (1) JP2004516265A (cg-RX-API-DMAC7.html)
CN (1) CN1359677A (cg-RX-API-DMAC7.html)
AU (1) AU7592501A (cg-RX-API-DMAC7.html)
BR (1) BR0109769A (cg-RX-API-DMAC7.html)
CA (1) CA2397990A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA02008097A (cg-RX-API-DMAC7.html)
RU (1) RU2244545C2 (cg-RX-API-DMAC7.html)
UA (1) UA73970C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002049631A1 (cg-RX-API-DMAC7.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
ES2211151T3 (es) 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
EP1490030B2 (en) * 2002-03-20 2010-07-14 Elan Pharma International Limited Nanoparticulate compositions of angiogenesis inhibitors
JP2006504771A (ja) * 2002-10-29 2006-02-09 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド システインを伴うプロポフォール
JP2006524632A (ja) 2002-12-09 2006-11-02 アメリカン バイオサイエンス、インコーポレイテッド 組成物及び薬物送達方法
US7468394B1 (en) * 2003-03-11 2008-12-23 Amphastar Pharmaceuticals, Inc. Sterile pharmaceutical composition and process for a solution of propofol emulsion having microbial growth retardation
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) * 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US8546453B2 (en) 2003-08-14 2013-10-01 Rensheng Zhang Propofol compositions and methods for reducing pain associated with propofol injection
RU2290169C1 (ru) * 2005-06-23 2006-12-27 Открытое Акционерное Общество "Фаберлик" Косметическое и/или дерматологическое средство и антиоксидант
TR200801336T1 (tr) 2005-08-31 2008-08-21 Abraxis Bioscience, Inc. Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler.
KR101457834B1 (ko) * 2005-08-31 2014-11-05 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조 방법
CN101411685B (zh) * 2007-10-19 2011-04-20 上海医药工业研究院 一种静脉麻醉药2,6-二异丙基苯酚微乳组合物及其制备方法
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
BR112013016661B1 (pt) * 2011-01-04 2021-08-03 Novaliq Gmbh Emulsões de o/a compreendendo alcanos semifluorados
BR112013022213A2 (pt) * 2011-03-04 2017-05-02 Gruenenthal Gmbh administração parenteral de tapentadol
DK2680834T3 (en) 2011-03-04 2017-12-04 Gruenenthal Gmbh Semi-solid aqueous pharmaceutical composition containing tapentadol
JP2019142972A (ja) * 2011-03-04 2019-08-29 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口的投与
EP2680832B1 (en) 2011-03-04 2019-09-04 Grünenthal GmbH Aqueous pharmaceutical formulation of tapentadol for oral administration
EP2714010B1 (en) 2011-05-25 2017-03-01 Novaliq GmbH Topical pharmaceutical composition based on semifluorinated alkanes
JP2013001700A (ja) * 2011-06-21 2013-01-07 Fujifilm Corp プロポフォール含有水中油型エマルション組成物
JP5759804B2 (ja) * 2011-06-27 2015-08-05 富士フイルム株式会社 容器詰製剤
DK2806886T3 (en) 2012-01-23 2017-06-06 Novaliq Gmbh STABILIZED PROTEIN COMPOSITIONS BASED ON SEMIFLUORED ALKANES
WO2013172999A1 (en) 2012-05-16 2013-11-21 Mewa Singh Pharmaceutical compositions for the delivery of substantially water-insoluble drugs
EP3488847B1 (en) 2012-09-12 2023-11-08 Novaliq GmbH Semifluorinated alkane compositions
AU2013314370B2 (en) 2012-09-12 2017-11-30 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
WO2015011199A1 (en) 2013-07-23 2015-01-29 Novaliq Gmbh Stabilized antibody compositions
BR112017018569A2 (pt) 2015-03-27 2018-04-24 Gruenenthal Gmbh formulação estável para administração parentérica de tapentadol
US10821087B2 (en) * 2015-07-24 2020-11-03 Neon Laboratories Limited Stabilized injectable emulsion of Propofol and Ketamine
WO2017031261A1 (en) 2015-08-20 2017-02-23 Mewa Singh Polyphenolic polymer to make water-insoluble molecules become water-soluble
EP3495023B1 (en) 2015-09-30 2020-04-22 Novaliq GmbH Semifluorinated compounds and their compositions
KR102584063B1 (ko) 2015-09-30 2023-09-27 노바리크 게엠베하 부분불소화 화합물
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
KR102614858B1 (ko) 2016-09-22 2023-12-18 노바리크 게엠베하 안검염 치료에 사용되는 약제학적 조성물
CA3036306C (en) 2016-09-23 2024-05-14 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
WO2018055070A1 (en) 2016-09-23 2018-03-29 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
JP7032404B2 (ja) 2016-12-23 2022-03-08 ノバリック ゲーエムベーハー ドライアイ疾患の治療のための眼科用組成物
JP7072582B2 (ja) 2017-04-21 2022-05-20 ノバリック ゲーエムベーハー ヨウ素組成物
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
US11723861B2 (en) 2017-09-27 2023-08-15 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
EP3758676A1 (en) 2018-03-02 2021-01-06 Novaliq GmbH Pharmaceutical compositions comprising nebivolol
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
JP7500550B2 (ja) 2018-10-12 2024-06-17 ノバリック ゲーエムベーハー 乾性眼疾患の治療のための眼科用組成物
WO2020165132A1 (en) 2019-02-13 2020-08-20 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
ES2211151T3 (es) * 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6100302A (en) * 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics

Also Published As

Publication number Publication date
BR0109769A (pt) 2003-02-04
WO2002049631A1 (en) 2002-06-27
EP1250130A1 (en) 2002-10-23
UA73970C2 (en) 2005-10-17
US6399087B1 (en) 2002-06-04
RU2002122394A (ru) 2004-03-20
CN1359677A (zh) 2002-07-24
CA2397990A1 (en) 2002-06-27
JP2004516265A (ja) 2004-06-03
AU7592501A (en) 2002-07-01
EP1250130A4 (en) 2006-03-15
RU2244545C2 (ru) 2005-01-20

Similar Documents

Publication Publication Date Title
MXPA02008097A (es) Formulacion de propol con inhibicion microbiana mejorada.
ES2177422A1 (es) Composiciones acaricidas.
CA2366793A1 (en) Propofol formulation with enhanced microbial characteristics
FI982009A7 (fi) Propofolin mikropisaraformulaatioita
DE60220415D1 (de) Flavonoide und mehrfach ungesättigte fettsäuren enthaltende natürliche phospholipide maritimen ursprungs sowie deren anwendungen
ES2182513T3 (es) Enriquecimiento de una grasa vegetal con antioxidantes.
BRPI0608690B8 (pt) uso de uma composição antimicrobiana
WO2007136597A3 (en) Silicone surfactant-based agricultural formulations and methods for the use therof
AR043383A1 (es) Formulaciones herbicidas de glisofato de elevada resistencia y baja viscosidad
AR044248A1 (es) Agentes para combatir parasitos en animales
PA8553201A1 (es) Formulaciones en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otras sustancias activas, y su utilizacion
NO20015176D0 (no) Anvendelse av kreatin som fortilsats
UA89315C2 (en) Butylbenzene phthalein intravenous emulsion
EP1852114A4 (en) COMPOSITION WITH DIHOMO (GAMMA) LINE ACIDIC ACID (DGLA) AS AN ACTIVE INGREDIENTS
CR5837A (es) Combinaciones fungicidas que comprenden derivados de aceidofenilacrilico
DK1315421T3 (da) Organophosphorsammensætninger
AR032374A1 (es) Dispositivo para aplicar por derrame un pesticida sobre un animal
WO2004100935A3 (en) Propofol formulation containing reduced oil and surfactants
DE50200148D1 (de) Mittel zur Bekämpfung von Mikroorganismen, enthaltend einen wirksamen Gehalt an Estern des Polyglycerins
DE602004014787D1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
RU2001126854A (ru) Повязка для лечения ран
AR022294A1 (es) Combinaciones de productos activos fungicidas.
ITRM20030485A1 (it) Composizione a base di citicolina in associazione con vitamine per la prevenzione ed il trattamento di patolgie oculari.
PT935918E (pt) Composicoes anti-bacterianas activas contra ralstonia solanacearum
DOP2002000427A (es) Un polvo de condimento y/o de caldo y el procedimiento para prepararlo.

Legal Events

Date Code Title Description
FG Grant or registration